MedTrace Logo

Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19

NCT04542694 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-11-05

Study results available
· View outcomes & findings →

Summary

This is open-labe randomized multicenter comparative Phase III study conducted in 5 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir compared with the Standard of care (SOC) in hospitalized patients with moderate COVID-19 pneumonia.

Conditions

Interventions

DRUG

Favipiravir

200 mg coated tablets

DRUG

Standard of care

Drug: Standard of Care Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator. Other Name: Hydroxychloroquine, chloroquine, lopinavir/ritonavir, etc.

Sponsors & Collaborators

  • Promomed, LLC

    lead OTHER

Principal Investigators

  • Dmitriy Pushkar · Moscow State Clinical Hospital №50

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-21
Primary Completion
2020-08-10
Completion
2020-08-20

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04542694 on ClinicalTrials.gov